Analyst Reco. Seres Therapeutics, Inc.

Equities

MCRB

US81750R1023

Real-time Estimate Cboe BZX Other stock markets 01:57:52 2024-04-26 pm EDT			5-day change	1st Jan Change
0.797 ^USD	+7.31%		+41.60%	-43.37%

06:44pm	Foreign automakers eager for Chinese partners at Beijing auto show	RE
Apr. 25	Battle for 'tech luxury' in China as EVs get smarter - and cheaper	RE

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Adjusts Seres Therapeutics Price Target to $5 From $9, Maintains Outperform Rating	Mar. 06	MT
Chardan Cuts Price Target on Seres Therapeutics to $8 From $10 on Higher Expected Sharecount Dilution, Keeps Buy Rating	Mar. 06	MT
Oppenheimer Trims Seres Therapeutics Price Target to $9 From $10, Maintains Outperform Rating	Jan. 16	MT
Goldman Sachs Adjusts Price Target on Seres Therapeutics to $1.25 From $4, Maintains Sell Rating	Nov. 03	MT
Oppenheimer Adjusts Seres Therapeutics Price Target to $10 From $12, Maintains Outperform Rating	Nov. 03	MT
Chardan Cuts Price Target on Seres Therapeutics to $10 From $12, Keeps Buy Rating	23-04-28	MT
JPMorgan Starts Seres Therapeutics at Neutral	23-04-21	MT
Canaccord Genuity Adjusts Price Target on Seres Therapeutics to $15 From $11, Maintains Buy Rating	23-03-21	MT
Canaccord Genuity Lowers Price Target on Seres Therapeutics to $11 From $17, Maintains Buy Rating	23-03-08	MT
Piper Sandler Adjusts Price Target on Seres Therapeutics to $9 From $7, Reiterates Overweight Rating	22-09-07	MT
Chardan Capital Lowers Seres Therapeutics Price Target to $12 From $16, Maintains Buy Rating	22-08-04	MT
Oppenheimer Adjusts Seres Therapeutics' Price Target to $12 From $13, Maintains Outperform Rating	22-08-04	MT
Piper Sandler Lowers Seres Therapeutics' to $7 From $32, Overweight Rating Kept	22-05-23	MT
Oppenheimer Adjusts Seres Therapeutics Price Target to $13 From $16, Maintains Outperform Rating	22-03-02	MT
SERES THERAPEUTICS : Oppenheimer Adjusts Seres Therapeutics PT to $18 From $36, Maintains Outperform Rating	21-07-23	MT
SERES THERAPEUTICS : Chardan Adjusts Price Target on Seres Therapeutics to $16 From $30 After Drug Disappoints in Study, Maintains Buy Rating	21-07-23	MT
SERES THERAPEUTICS : Canaccord Genuity Adjusts Seres Therapeutics' Price Target to $29 From $42, Maintains Buy Rating	21-07-23	MT
SERES THERAPEUTICS : HC Wainwright Adjusts Seres Therapeutics' Price Target to $25 From $46, Keeps Buy Rating	21-07-23	MT
SERES THERAPEUTICS : Goldman Sachs Cuts Seres Therapeutics to Sell From Neutral, Price Target to $7 From $24	21-07-23	MT
SERES THERAPEUTICS : Piper Sandler Adjusts Price Target on Seres Therapeutics to $40 From $47, Maintains Overweight Rating	21-07-02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Seres Therapeutics, Inc.

Equities

MCRB

US81750R1023

Analyst Reco.

Filters